Get the Stockscreener App
24.83
2.60%
0.63
Pharvaris Nv stock is traded at $24.83, with a volume of 474.84K.
It is up +2.60% in the last 24 hours and up +3.50% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$24.20
Open:
$24.24
24h Volume:
474.84K
Relative Volume:
2.06
Market Cap:
$1.57B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-8.7937
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
+5.44%
1M Performance:
+3.50%
6M Performance:
+51.40%
1Y Performance:
+18.01%
1-Day Range:
$23.76
$25.45
1-Week Range:
$23.01
$26.20
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
24.83 | 1.57B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
Is Pharvaris N.V. (9EN) stock attractive for growth fundsJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Pharvaris NV (PHVS) can make a big difference with a little luck - Setenews
Why Pharvaris N.V. (9EN) stock could outperform next yearPortfolio Update Summary & Stepwise Swing Trade Plans - newser.com
Why Pharvaris N.V. stock remains on watchlists2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Is Pharvaris N.V. (9EN) stock undervalued after correctionPortfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Can you recover from losses in Pharvaris N.V.Earnings Recap Summary & Consistent Profit Trading Strategies - newser.com
Why Pharvaris N.V. stock is in analyst buy zoneJuly 2025 Market Mood & AI Forecasted Entry/Exit Points - newser.com
How Pharvaris N.V. (9EN) stock trades in high volatilityMarket Movement Recap & High Accuracy Swing Entry Alerts - newser.com
Can Pharvaris N.V. (9EN) stock reach $200 price target2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
Published on: 2025-11-19 13:25:31 - newser.com
Citizens reiterates Market Outperform rating on Pharvaris stock ahead of trial data - Investing.com UK
Trading Systems Reacting to (PHVS) Volatility - news.stocktradersdaily.com
Will Pharvaris N.V. stock attract ESG investorsJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
Why Bain Capital Is Selling Shares of This Biotech Stock Now - The Motley Fool
How sentiment analysis helps forecast Pharvaris N.V.July 2025 Snapshot & Risk Controlled Daily Trade Plans - newser.com
Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume After Analyst Upgrade - Defense World
Cantor Fitzgerald Boosts Earnings Estimates for Pharvaris - Defense World
What is Wedbush’s Estimate for Pharvaris FY2025 Earnings? - Defense World
Pharvaris FY2025 EPS Estimate Boosted by Leerink Partnrs - Defense World
Visual analytics tools that track Pharvaris N.V. performanceJuly 2025 Final Week & Technical Pattern Recognition Alerts - newser.com
What recovery options are there for Pharvaris N.V.2025 Fundamental Recap & Safe Swing Trade Setup Alerts - newser.com
Wedbush Has Negative Estimate for Pharvaris FY2029 Earnings - Defense World
Is Pharvaris N.V. stock safe for conservative investorsIPO Watch & Verified Technical Trade Signals - newser.com
Custom watchlist performance reports with Pharvaris N.V.Portfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Pharvaris (NASDAQ:PHVS) Earns Buy Rating from HC Wainwright - Defense World
Can Pharvaris N.V. (9EN) stock deliver strong annual returnsJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Morgan Stanley Maintains Pharvaris N.V. (PHVS) Overweight Recommendation - MSN
Full technical analysis of Pharvaris N.V. stockWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Why Pharvaris N.V. (9EN) stock attracts HNW investors2025 Trading Recap & Free Community Supported Trade Ideas - Fundação Cultural do Pará
Technical signs of recovery in Pharvaris N.V.Trade Entry Report & Reliable Price Breakout Signals - newser.com
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):